Abstract: The invention relates to the ADH3 promoter; polynucleotide sequences, vectors and expression cassettes including DNA regions responsible for the regulation of the ADH3 promoter; the host cells, including these vectors and expression cassettes, and, the recombinant proteins performed with the developed cells. In the scope of the invention, deletion analyzes in the ADH3 promoter were performed to identify regions that affect promoter strength and significant data was obtained in the formation of mutant ADH3 promoters. Deletion of the nucleotides between 539 and 638 (?361 to ?262) in SEQ ID NO: 1 resulted in a 63% increase in ADH3 promoter activity. Five different synthetic promoters were created using positive regulatory regions identified and approximately 165% to 200% promoter activities were achieved with these promoters.
Type:
Grant
Filed:
February 14, 2019
Date of Patent:
May 9, 2023
Assignee:
AKDENIZ UNIVERSITESI
Inventors:
Mehmet Inan, Mert Karaoglan, Fidan Erden Karaoglan
Abstract: The present invention relates to materials and methods for engineering, expression and high-level production of cost effective, safe and functional active recombinant truncated human Angiotensin-converting enzyme 2 (ACE2) in plants using transient expression system. In particular, the present invention relates to the production of glycosylated and non-glycosylated forms of ACE2 polypeptide in Nicotiana benthamiana (N. benthamiana) plant. The cost effective, safe and functional active plant produced recombinant ACE2 polypeptides can be used as a potential therapeutic target in COVID-19 patients to block or slow down the virus entering, spread of the virus and protect the lung from injury, also recombinant ACE2 enzymes are used as potential drugs to treat patients by controlling blood pressure.
Abstract: The invention relates to the ADH3 promoter, polynucleotide sequences, vectors and expression cassettes including DNA regions responsible for the regulation of the ADH3 promoter; the host cells, including these vectors and expression cassettes, and, the recombinant proteins performed with the developed cells. In the scope of the invention, deletion analyzes in the ADH3 promoter were performed to identify regions that affect promoter strength and significant data was obtained in the formation of mutant ADH3 promoters. Deletion of the nucleotides between 539 and 638 (?361 to ?262) in SEQ ID NO: 1 resulted in a 63% increase in ADH3 promoter activity. Five different synthetic promoters were created using positive regulatory regions identified and approximately 165% to 200% promoter activities were achieved with these promoters.
Type:
Application
Filed:
February 14, 2019
Publication date:
December 30, 2021
Applicant:
AKDENIZ UNIVERSITESI
Inventors:
Mehmet INAN, Mert KARAOGLAN, Fidan ERDEN KARAOGLAN